Monoclonal antibody capable of activating T cells and cloned T cell lines.
| Institute |
|---|
| Yale University |
| Cat. #: | 155246 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Target: | CD3 |
| Host: | Hamster |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody capable of activating T cells and cloned T cell lines. The CD3 complex, composed of four distinct CD3 polypeptide chains (CD3γ, CD3δ and 2X CD3Ɛ), associates with the T cell antigen receptor (TCR. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction. CD3 may play a role in TCR-induced growth arrest, cell survival and proliferation. The CD3 antigen is present on 68-82% of normal peripheral blood lymphocytes, 65-85% of thymocytes and Purkinje cells in the cerebellum. It is never expressed on B or NK cells. Decreased percentages of T lymphocytes may be observed in some autoimmune diseases. This antibody activates cloned T cell lines and normal T cells, provided suitable accessory cells and signals are present. Binding of anti-CD3 (500.A2) to CD3 initiates the intracellular biochemical pathway resulting in cellular activation and proliferation. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Immunogen: | 25-kDa e chain of the T-cell receptor-associated CD3 complex |
| Immunogen Uniprot ID: | A0A3Q0CNZ4 |
| Target background: | Monoclonal antibody capable of activating T cells and cloned T cell lines.Background and Research ApplicationThe CD3 complex, composed of four distinct CD3 polypeptide chains (CD3γ, CD3δ and 2X CD3Ɛ), associates with the T cell antigen receptor (TCR. CD3 is a member of the immunoglobulin superfamily, involved in antigen recognition, T lymphocyte activation and signal transduction. CD3 may play a role in TCR-induced growth arrest, cell survival and proliferation. The CD3 antigen is present on 68-82% of normal peripheral blood lymphocytes, 65-85% of thymocytes and Purkinje cells in the cerebellum. It is never expressed on B or NK cells. Decreased percentages of T lymphocytes may be observed in some autoimmune diseases.This antibody activates cloned T cell lines and normal T cells, provided suitable accessory cells and signals are present. Binding of anti-CD3 (500.A2) to CD3 initiates the intracellular biochemical pathway resulting in cellular activation and proliferation. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Chen et al. 2019. JCI Insight. 4(22):. PMID: 31723059. Trittel et al. 2019. Sci Rep. 9(1):16362. PMID: 31704965. Czarnewski et al. 2019. Nat Commun. 10(1):2892. PMID: 31253778. Zwick et al. 2019. Front Immunol. 10:222. PMID: 30809231. Shahbaz et al. 2018. PLoS Biol. 16(12):e2006649. PMID: 30550561. Maj et al. 2017. Nat Immunol. 18(12):1332-1341. PMID: 29083399. Long et al. 2016. Genes (Basel). 8(1):. PMID: 28035981. Portoles et al. 1989. J Immunol. 142(12):4169-75. PMID: 2470817. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.